MedPath

Hepcidin Behavior in Patients With Obesity and Bariatric Surgery

Terminated
Conditions
Hepcidin
Interventions
Other: Blood sampling
Registration Number
NCT03990948
Lead Sponsor
Universitaire Ziekenhuizen KU Leuven
Brief Summary

Iron deficiency is one of the most common nutritional problems observed in patients with obesity and after bariatric surgery. From a therapeutic point of view, iron deficiency can lead to iron deficiency anemia. Iron supplementation carries the risk of exacerbating infections, altering the gut microbiome and iron overload. Therefore, it would be beneficial to use iron supplementation only in truly iron deficient patients. To date, different studies have observed that hepcidin could be a possible indicator of iron status and absorption in different patient populations. Furthermore, it could be used to distinguish anemia due to iron deficiency from inflammation and globin disorder related anemia. How hepcidin concentrations variate in patients with obesity and after bariatric surgery remains unsure.

Detailed Description

During the visit in the obesity clinic, eligible patients will be approached for participation by the sub-investigator. Interested patients will receive information regarding the study and receive the information sheet containing the informed consent form. After signing the informed consent form, general information will be collected regarding medical and demographic data using a short questionnaire. Additional questionnaires regarding demographics and menstrual cycle will be collected. Anthropometric measurements will be collected for the determination of the length, weight, hip circumference, waist circumference and body composition. Finally, blood samples will be collected for the determination of iron and inflammation related markers.

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
300
Inclusion Criteria
  • The patient has to be 18 years or older
  • Written informed consent has to be obtained after being informed on all aspects of the study
  • The patient has a BMI > 30 kg/m² OR There has to be at least one year between the primary RYGB and the participation in the study OR There has to be at least one year between the primary SG and the participation in the study
Exclusion Criteria
  • Patients younger than 18 years old
  • Women who are pregnant or are breastfeeding
  • Post-menopausal women, defined as at least 6 months of amenorrhea after the final menstrual period
  • Inability to follow the procedures of the studies due to language problems
  • Patients who have had more than one bariatric surgery

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Patients with obesityBlood samplingIn 100 patients with obesity, blood samples will be collected.
Patients with a Sleeve GastrectomyBlood samplingIn 100 patients with a Sleeve Gastrectomy, blood samples will be collected.
Patients with a Roux-en-Y Gastric BypassBlood samplingIn 100 patients with a Roux-en-Y Gastric Bypass, blood samples will be collected.
Primary Outcome Measures
NameTimeMethod
Serum hepcidin concentrationStudy visit 1 day

Serum hepcidin concentration

Secondary Outcome Measures
NameTimeMethod
Ferritin concentrationStudy visit 1 day

Ferritin concentration

Vitamin B12 concentrationStudy visit 1 day

Vitamin B12 concentration

Folate (RBC level)Study visit 1 day

Folate (RBC level)

Hemoglobin concentrationStudy visit 1 day

Hemoglobin concentration

Mean corpuscular volumeStudy visit 1 day

Mean corpuscular volume

Iron concentrationStudy visit 1 day

Iron concentration

Transferrin concentrationStudy visit 1 day

Transferrin concentration

Transferrin saturationStudy visit 1 day

Transferrin saturation

Folate (serum level)Study visit 1 day

Folate (serum level)

C-reactive proteinStudy visit 1 day

C-reactive protein

Trial Locations

Locations (1)

UZ Leuven

🇧🇪

Leuven, Belgium

© Copyright 2025. All Rights Reserved by MedPath